We are live on ! Find out more
BMRN icon

BioMarin Pharmaceuticals
BMRN

547 hedge funds and large institutions have $18B invested in BioMarin Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 85 funds opening new positions, 178 increasing their positions, 207 reducing their positions, and 50 closing their positions.

New
Increased
Maintained
Reduced
Closed

70% more first-time investments, than exits

New positions opened: 85 | Existing positions closed: 50

36% more call options, than puts

Call options by funds: $193M | Put options by funds: $141M

12% more capital invested

Capital invested by funds: $16.1B → $18B (+$1.96B)

5% more funds holding

Funds holding: 519 → 547 (+28)

2.79% more ownership

Funds ownership: 96.45% → 99.24% (+2.8%)

0% more funds holding in top 10

Funds holding in top 10: 14 → 14 (0)

14% less repeat investments, than reductions

Existing positions increased: 178 | Existing positions reduced: 207

Holders
547
Holders Change
+28
Holders Change %
+5.39%
% of All Funds
7.97%
Holding in Top 10
14
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.2%
New
85
Increased
178
Reduced
207
Closed
50
Calls
$193M
Puts
$141M
Net Calls
+$51.4M
Net Calls Change
-$924K

Top Buyers

Rank Fund Capital Flow
1
Capital Research Global Investors
Capital Research Global Investors
California
+$421M
2
EIM
Elliott Investment Management
Florida
+$265M
3
Deutsche Bank
Deutsche Bank
Germany
+$177M
4
Morgan Stanley
Morgan Stanley
New York
+$99M
5
Millennium Management
Millennium Management
New York
+$80M

Top Sellers

Rank Fund Capital Flow
1
BBA
Baker Bros. Advisors
New York
-$337M
2
Nomura Holdings
Nomura Holdings
Japan
-$62.6M
3
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$56.1M
4
Pictet Asset Management
Pictet Asset Management
Switzerland
-$44.7M
5
PHS
PFM Health Sciences
California
-$44.1M
Name Holding Trade Value Shares
Change 		Change in
Stake
IIM
226
INTECH Investment Management
Florida
$2.43M -$349K -3,949 -14%
HR
227
Howe & Rusling
New York
$2.37M +$2.74K +31 +0.1%
Bank Julius Baer & Co
228
Bank Julius Baer & Co
Switzerland
$2.35M +$1.01M +11,405 +80%
SIA
229
Sit Investment Associates
Minnesota
$2.27M – – –
SF
230
Synovus Financial
Georgia
$2.24M +$5.75K +65 +0.3%
PI
231
PineBridge Investments
New York
$2.24M +$516K +5,830 +34%
CAC
232
Cowen and Company
New York
$2.2M +$2.02M +22,865 New
CUAMC
233
China Universal Asset Management Company
China
$2.14M +$1.17M +13,270 +149%
Public Employees Retirement Association of Colorado
234
Public Employees Retirement Association of Colorado
Colorado
$2.12M -$96.9K -1,095 -5%
FC
235
FORA Capital
Florida
$2.12M +$1.95M +22,001 New
BCIM
236
British Columbia Investment Management
British Columbia, Canada
$2.09M +$407K +4,601 +27%
Walleye Trading
237
Walleye Trading
New York
$2.08M +$668K +7,555 +54%
TMAM
238
Tokio Marine Asset Management
Japan
$2.04M -$24.1K -272 -1%
NAM
239
Nissay Asset Management
Japan
$2.02M +$64.5K +729 +4%
SAM
240
Storebrand Asset Management
Norway
$2.01M +$165K +1,860 +10%
BCI
241
Brinker Capital Investments
Pennsylvania
$2M -$190K -2,150 -10%
OPS
242
Orion Portfolio Solutions
Nebraska
$2M -$190K -2,150 -10%
TSS
243
Two Sigma Securities
New York
$1.96M +$1.11M +12,552 +162%
Osaic Holdings
244
Osaic Holdings
Arizona
$1.94M -$308K -3,481 -15%
TCA
245
Taconic Capital Advisors
New York
$1.93M +$1.77M +20,000 New
Daiwa Securities Group
246
Daiwa Securities Group
Japan
$1.91M +$33.5K +379 +2%
LTAS
247
Linden Thomas Advisory Services
North Carolina
$1.72M -$14.7K -166 -0.9%
WAM
248
Weiss Asset Management
Massachusetts
$1.72M +$1.58M +17,849 New
BPA
249
Beacon Pointe Advisors
California
$1.72M -$11.8K -133 -0.7%
GAM
250
Griffin Asset Management
New York
$1.68M +$40.1K +453 +3%
8 9
10
11 12

BMRN Hedge Fund Activity: Q4 2023 in Review

547 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in BioMarin Pharmaceuticals (BMRN) for Q4 2023, worth a combined $18B — up 12% from $16.1B a quarter earlier.

Buyers outnumbered sellers: 85 funds opened new BMRN positions and 50 closed out — a net gain of 35 holders — while 178 added to existing stakes and 207 trimmed.

The largest buyer was Capital Research Global Investors, adding an estimated $421M. The largest seller was Baker Bros. Advisors, exiting entirely with an estimated $337M sold.

  • 547 institutional investors held BioMarin Pharmaceuticals (BMRN) as of Q4 2023, up from 519 in Q3 2023.
  • Funds reported $18B of BioMarin Pharmaceuticals stock for Q4 2023, up 12% quarter-over-quarter.
  • 85 funds opened new BioMarin Pharmaceuticals positions in Q4 2023 and 50 closed out, a net change of +35 holders.
  • The largest BioMarin Pharmaceuticals buyer in Q4 2023 was Capital Research Global Investors, an estimated $421M added.
  • The largest BioMarin Pharmaceuticals seller in Q4 2023 was Baker Bros. Advisors, an estimated $337M sold.

Based on aggregated 13F filings for Q4 2023.